Item 6. SELECTED FINANCIAL DATA

8K characters. Original on sec.gov · Markdown

Item 6. SELECTED FINANCIAL DATA

The following should be read in conjunction with the consolidated financial statements, including the notes thereto, and Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on page 26.


	As of or for the Fiscal Year Ended September 30,
(Amounts in thousands, except per share amounts)	2020(a)		2019(b)		2018(c)		2017(d)		2016(e)
Statement of Operations Data:
Revenue	$	189,893,926	$	179,589,121	$	167,939,635	$	153,143,826	$	146,849,686
Gross profit	5,191,884		5,138,312		4,612,317		4,546,002		4,272,606
Operating expenses	10,327,238		4,026,389		3,168,632		3,485,660		2,746,832
Operating (loss) income	(5,135,354)		1,111,923		1,443,685		1,060,342		1,525,774
Interest expense, net	137,883		157,769		174,699		145,185		139,912
Net (loss) income	(3,399,558)		854,135		1,615,892		364,484		1,427,929
Net (loss) income attributable to AmerisourceBergen Corporation	$	(3,408,716)	$	855,365	$	1,658,405	$	364,484	$	1,427,929
Earnings per share — diluted	$	(16.65)	$	4.04	$	7.53	$	1.64	$	6.32
Cash dividends declared per common share	$	1.66	$	1.60	$	1.52	$	1.46	$	1.36
Weighted average common shares outstanding — diluted	204,783		211,840		220,336		221,602		225,959
Balance Sheet Data:
Cash and cash equivalents	$	4,597,746	$	3,374,194	$	2,492,516	$	2,435,115	$	2,741,832
Accounts receivable, net	13,846,301		12,386,879		11,314,226		10,303,324		9,175,876
Inventories	12,589,278		11,060,254		11,918,508		11,461,428		10,723,920
Property and equipment, net	1,484,808		1,770,516		1,892,424		1,797,945		1,530,682
Total assets	44,274,830		39,171,980		37,669,838		35,316,470		33,637,501
Accounts payable	31,705,055		28,385,074		26,836,873		25,404,042		23,926,320
Total debt	4,119,520		4,172,892		4,310,189		3,442,055		4,186,703
Total accrued litigation liability	6,606,925		—		—		—		—
Total (deficit) equity	(839,636)		2,993,206		3,049,961		2,064,461		2,129,404
Total liabilities and stockholders' (deficit) equity	$	44,274,830	$	39,171,980	$	37,669,838	$	35,316,470	$	33,637,501

(a)Includes a $5,528.4 million legal accrual for litigation relating the distribution of prescription opioid pain medications, net of income tax benefit of $1,078.6 million; $282.5 million impairment of PharMEDium's long-lived assets, net of income tax benefit of $79.2 million; $156.5 million of employee severance, litigation, and other costs, net of income tax benefit of $43.9 million; $46.4 million of PharMEDium exit and remediation costs, net of income tax benefit of $13.0 million; a $17.3 million loss on early retirement of debt; net of income tax benefit of $4.9 million; an $11.6 million estimated assessment related to the New York State Opioid Stewardship Act, net of income tax benefit of $3.2 million; a $9.5 million gain from an adjustment to Profarma's estimate of contingent consideration related to the purchase price of one of its prior business acquisitions, net of income tax expense of $2.7 million; a $7.1 million gain from antitrust litigation settlements, net of income tax expense of $2.0 million; and $5.8 million of LIFO expense, net of income tax benefit of $1.6 million.

(b)Includes a $421.3 million impairment of PharMEDium's long-lived assets, net of income tax benefit of $148.7 million; $245.8 million of employee severance, litigation, and other costs, net of income tax benefit of $84.6 million; a $107.8 million gain from antitrust litigation settlements, net of income tax expense of $38.1 million; $51.3 million of PharMEDium remediation costs, net of income tax benefit of $18.1 million; a $16.7 million LIFO credit, net of income tax expense of $5.9 million; a $16.3 million reversal of an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax expense of $5.7 million; and a $10.1 million gain on the sale of an equity investment, net of income tax expense of $3.6 million.

(c)Includes $61.3 million of employee severance, litigation, and other costs, net of income tax benefit of $122.2 million; a $59.7 million goodwill impairment with no income tax benefit; $48.6 million of LIFO expense, net of income tax benefit of $18.7 million; $47.8 million of PharMEDium remediation costs, net of income tax benefit of $18.4 million; a $42.3 million loss on consolidation of equity investments with no income tax benefit; a $30.0 million impairment on a non-customer note receivable with no income tax benefit; a $25.9 million gain from antitrust litigation settlements, net of income tax expense of $10.0 million; a $17.2 million loss on early retirement of debt, net of income tax benefit of $6.6 million; and $15.9 million of expense for an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax benefit of $6.1 million.

(d)Includes a $101.1 million LIFO credit, net of income tax expense of $56.7 million; a $0.9 million gain from antitrust litigation settlements, net of income tax expense of $0.5 million; and $937.4 million of employee severance, litigation, and other costs, net of income tax benefit of $21.9 million.

(e)Includes $367.2 million of Warrants income, net of income tax benefit of $507.5 million; $120.9 million of LIFO expense, net of income tax benefit of $79.3 million; an $80.8 million gain from antitrust litigation settlements, net of income tax expense of $53.0 million; $62.1 million of employee severance, litigation, and other costs, net of income tax benefit of $40.8 million; and a $28.7 million pension settlement charge, net of income tax benefit of $18.9 million.

Previous: Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES · Next: Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS